Skip to search formSkip to main contentSkip to account menu

HuC242-DM4

Known as: CANTUZUMAB RAVTANSINE, IMGN242, Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 
An immunotoxin of a humanized monoclonal antibody C242 (MoAb HuC242) conjugated to a derivative of the cytotoxic agent maytansine, DM4, with… 
National Institutes of Health

Related topics

Related topics

1 relation
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Additional file 2: Figure S1. of Indatuximab ravtansine (BT062) combination treatment in multiple myeloma: pre-clinical studies
2017
2017
AB027. PS01.09. In-progress: phase 1b study of anetumab ravtansine in patients with mesothelin-expressing malignancies
2016
2016
Abstract 2967:In vitroandin vivoactivity of site-specific antibody-drug conjugates (ADCs) with 2 and 4 maytansinoid molecules per antibody prepared through conjugation to SeriMabs (N-terminal serine…
Site-specific attachment of cell-killing agents to antibodies directed against tumor-associated antigens has continued to be an… 
2013
2013
Abstract 4324: Maytansinoid conjugates of a novel type III anti-CD20 antibody with potent antitumor activity.
Previously identified anti-CD20 antibodies have been classified as either Type I antibodies with lipid raft and complement… 
2010
2010
apeutic Discovery tansinoid-Antibody Conjugates Induce Mitotic Arrest by Ther pressing Microtubule Dynamic Instability
Download tansine and its analogues (maytansinoids) are potent microtubule-targeted compounds that inhibit ration of cells at… 
2008
2008
The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors
3066 Background: IMGN242 is a targeted anticancer agent in development for treating CanAg-expressing tumors. In a Phase I… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2003
2003
In vitro and in vivo antitumor activity of the maytansinoid immunoconjugate BB-10901 (huN901-DM1) on CD56+multiple myeloma cells.
2003
2003
Cantuzumab M ertansine, a M aytansinoid I mmunoconjugate Directed t o t he C anAg A ntigen: A P hase I , P harmacokinetic, and B iologic C orrelative S tudy
Purpose: To determine the maximum tolerated dose and pharmacokinetics of cantuzumab mertansine, an immunoconjugate of the potent… 
2002
2002
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)